Regarding disease activity, significant downregulation of lnc-EGFR and FOXP3 gene expression along with lower serum TGF-β1 levels were found in RRMS patients during active relapses and in remission compared to healthy control subjects. This evidence concerns the gene FOXP3 and relapsing-remitting multiple sclerosis.